Dr. Rath Research Institute, 1260 Memorex Drive, Santa Clara, USAEmail: email@example.com
After I graduated from Kyushu University Graduate School of Medical Sciences in 2004, I started junior residency at Kyushu Medical Center and Kyushu University hospital from 2004 to 2006. Next, I worked as a senior resident at Kyushu Cancer Center hospital in 2006. Then, I researched about cancer stem cells at Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science.
I got Diplomate, Subspeciality Board of Medical Oncology in 2012, and worked as a chief resident National Cancer Center Hospital, Tokyo. At National Cancer Center Hospital, I researched about esophageal cancer chemotherapy mainly.
Then, I joined and worked at the department of Gastrointestinal and Clinical Oncology Division of Kyushu Cancer Center Hospital from 2013 to 2015. From 2015 to 2017, I was a head of Oncology division of Miyazaki Prefectural Miyazaki Hospital, and a main and leading member of Kyushu Medical Oncology Group and Kyushu-Yamaguchi Total Oncology Group, respectively. Now in 2018, I work in Karatsu Higashi-matsuura Medical Association Center as a doctor of internal medicine.
Medical Oncology (Mainly Gastrointestinal Cancer), Cancer stem cell (Basic research), Palliative medicine, General Medicine, Gastroenterology, Clinical study, Multi-disciplinary coordination and multi-disciplinary study.
Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation. Rinsho Ketsueki. 2006 Oct;47(10):1372-6.
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol (2014) 74:1207-15, DOI 10.1007/s00280-014-2597-3.
Improvement in the awareness of palliative care nursing using STAS-J in an acute care hospital. J Palliat Care Med 2015, 5:3 http://dx.doi.org/10.4172/2165-7386.1000219.
Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. Anti-Cancer Drugs. 2016 Oct; 27(9): 891-8.
Analysis of a questionnaire survey regarding current conditions against exposure to anticancer drugs and reports of cancer chemotherapy at outpatient departments in Japan. Pharmacology & Pharmacy, 2017, 8, 140-152.
Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. Exp Cell Res. 2012 Sep 10;318(15):1799-807.
Human STEAP3 maintains tumor growth under hypoferric condition. Exp Cell Res. 2011 Nov 1;317(18):2582-91.
Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases. Anticancer research 2014, 34: 215-220.
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan. Anticancer research 2014, 34: 2035-2040.
Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan.
Anti-Cancer Drugs 2016, 27(5): 457-63.
Efficacy and Safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Research 2016 Apr; 36(4): 1959-66.
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol, 2016 Jul 15 DOI 10.1007/s00280-016-3106-7.
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer. 2017 May 11 DOI: 10.1007/s10120-017-0725-6.
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemotherapy Pharmacology, 2017 Jun 26. DOI 10.1007/s00280-017-3371-0.
Irinotecan mnotherapy as third-line or later treatment in advanved gastric cancer. Gastric Cancer, 21(3), 464-472 DOI 10.1007/s10120-017-0759-9.
Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. Anticancer Drugs, 2017 Sep 12 DOI 10.1097/CAD.0000000000000562.
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer. Anticancer Res. 2017 Nov;37(11):6459-6468.
Successful chemoradiotherapy for neuroendocrine tumor grade 3 arising from the mandibular gingiva: a case report and literature review. Open Journal of clinical & medical case report, Volume 2 (2016) Issue 5: 1089.
A complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report. Molecular and Clinical Oncology 2017 Jul; 7(1): 93-97.
Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body: a case report. J Med Case Rep. 2012, 6:315.
Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review. Int canc conf J. 2012 Oct DOI10.1007/s13691-012-0060-z.
Successful Chemoradiotherapy for undifferentiated malignant neoplasm arising from the left pulmonary artery Case Rep Oncol 2014;7:484-490.
Successful multimodal therapy for undifferentiated carcinoma with neuroendocrine differentiation in the clival region. Int canc conf J. 2014 July DOI 10.1007/s13961-014-0179-1.
Anti-HER2 combination chemotherapy for advanced gastric cancer associated with the Peutz-Jeghers syndrome: a case report and literature review. Int canc conf J. 2013 Nov DOI 10.1007/s13961-013-0139-1.
Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis. Molecular and Clinical Oncology 5: 579-582, 2016.
Research Interest: Current Professional Activity: Fibrilación Auricular, Miocardiopatía Hipertrófica, Micrornas,Remodelado Cardíaco
Research Interest: Her Major Scientific Interests Include Cancer Biology And Treatment, With Particular Emphasis On Sphingolipid Signalling In Cancer.
Research Interest: Medical Oncology (Mainly Gastrointestinal Cancer), Cancer Stem Cell, Palliative Medicine,Multi-Disciplinary Coordination And Multi-Disciplinary Study
Research Interest: Theoretical Chemistry, Physical Chemistry, Mathematical Chemistry, Computational Chemistry, Molecular Modelling, Simulation, And Design, Computer-Aided Drug Design And Development, Molecular Graphics And Representation Of Molecular Properties.
Research Interest: Gastric Cancer; Colon Cancer; Rectal Cancer; Interferon Regulatory Factor-1 (IRF-1); Chemotherapy; Drug Resistance; Telomerase
Research Interest: Potential Therapeutic Applications of Arteether, a Semi-Synthetized Derivative of Artemisinin on a Murine Model of Breast Cancer. As a Result, I Have Got Some Experience Atan Area of Tumor Immunology/Immunotherapynamed "Chemoimmunotherapy". Chemoimmunotherapy is an Approach for the Treatment of Cancers in Whichthe Focus is to enhance the Efficacy of chemotherapeutic Agents by Concomitant Application of Compounds with Immunomodulatory Properties. Besides my Thesis Work, I Managed to Do a Course in Cellular Immunology with Professor Hassan, One of the Well-Knownimmunologists in Iran, so that i could also Work on Cellular Immunology Aspects of Tumors. Moreover, Considering the Reported Associations between Molecular Players such as CTLA-4, PDL-1 and also Different Micrornas in Tumor Progression, i am Currently Planning to further Study these Associations in order to improve the Efficacy of Tumor Immunotherapy
Research Interest: To study the metabolic adaptation for survival occurring in the cancer cells
Former member of MGH, USA
International Journal of Immunotherapy and Cancer Research
Journal of Addiction Medicine and Therapeutic Science
Prof. Pierre Guertin
Laval University, Canada
International Journal of Pharmaceutical Sciences and Developmental Research
University of Siena, Italy
Archives of Renal Diseases and Management
Catholic University of Rome, Italy
Peertechz Journal of Orthopedics and Rheumatology